ArticleMedical molecular morphology2026
Genetic mutations in primary and metastatic tumors of a rare mixed neuroendocrine carcinoma and high-grade serous ovarian cancer.
Article in Medical molecular morphology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Neuroendocrine carcinoma and high-grade serous ovarian cancer (HGSCO) form a rare mixed ovarian tumor. Ovarian cancer is the most lethal gynecological malignancy, with HGSCO being the most common (60–70%) and aggressive subtype, characterized by insidious symptoms and poor prognosis. Neuroendocrine carcinoma (NEC) is a poorly differentiated, high-grade tumor. Their coexistence challenges individualized therapy and confers a poor prognosis. In this case, both components were present in the ovaries, with lung NEC nodules detected 2 years later. Second-generation sequencing revealed shared TP53, PRDM1, and KIT mutations in all three tumors, indicating a common origin from a pluripotent cancer stem cell and suggesting lung NEC metastasized from the ovary. A SPEN mutation was unique to HGSCO, implying a role in HGSCO differentiation, while a PLCG2 mutation occurred only in metastatic lung NEC, indicating a potential key role in lung metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.